A significant highlight on the horizon for the Phenomics Australia in vitro node the Monash Organoid Program is the eagerly anticipated annual Organoid Symposium, held on November 6th at the Monash University Clayton campus.
This event serves as a pivotal platform for knowledge exchange, fostering collaboration and innovation within the organoid research field.
The Organoid Symposium committee is currently working on the program, but we can already announce that some of the sessions will cover topics like cancer therapy, reproductive health, and more complex models, such as ‘assembloids’ and organ-on-a-chip.
This year, we have the pleasure to reveal the name of their renowned international Keynote speaker: Associate Professor Karuna Ganesh, a medical oncologist at Memorial Sloan Kettering Cancer Centre (NYC, USA). The Ganesh lab focuses on understanding the molecular mechanisms that underlie the emergence of regenerative plasticity during metastasis. Karuna’s team uses patient-derived organoids and mouse models of colorectal cancer, as well as transcriptomic, epigenomic and single-cell approaches, and mechanistic studies to: (1) elucidate how tumour invasion and dissemination induce phenotypic plasticity enabling the emergence of pro-metastatic regenerative traits (2) dissect the role of stromal cells, including immune cells, in promoting and constraining MetSC plasticity (3) define key signalling nodes that drive MetSC plasticity and develop therapeutic strategies for targeting such vulnerabilities and (4) collaborate with clinicians to understand mechanisms of therapy resistance in metastasis.
Please stay tuned for the registration link to come soon and the announcement of the official 2024 Monash Organoid Symposium program.
For more information see the links below:
Another successful Organoid Symposium at Monash for this 2023 edition
Monash BDI Organoid Program Symposium 2022: A Resounding Success
Phenomics Australia provides a national centre of expertise and service provision to deploy a more comprehensive and sophisticated range of in vitro Genome Engineering and Disease Modelling capabilities to understand the functional consequences of DNA sequence variation in the human genome for health and disease while maintaining the expertise for in vivo disease modelling and genome engineering. To meet the high demand for adaptable and scalable disease-modelling platforms for improved diagnosis, Precision Medicine for genetic disorders, and therapeutic development by both academia and the biopharmaceutical industry, Phenomics Australia offers In Vitro services through a collaborative consortium of ten laboratories and facilities across Australia, operating at ANU (ANU Centre for Therapeutic Discovery), Perkins (Translational Cancer Research Program in Oncology), Monash (Monash Organoid Program & Monash Genome Modification Platform), MCRI (iPSC derivation & Gene Editing Facility), Peter Mac (Victorian Centre for Functional Genomics), UMelb (Centre for Stem Cell Systems & Stem Cell Disease Modelling Laboratory), UQ (In vitro Genome Engineering and Disease Modelling Service), and VCCRI (Stem Cell Production Facility iPSC Reprogramming Service)
